Абдурахманов Джамал Тинович
Sechenov University · 113 works · 450 citations · h-index 12
Top works
- Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
- Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan
- Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance
- Persistent hepatitis C virus–associated cryoglobulinemic vasculitis following virus eradication after direct‐acting antiviral therapy
- Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
- Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection ( ESSENTIAL II )
- Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads
- Safe and effective treatment of follicular lymphoma in patients with HCV ‐infection
- Direct‐acting antiviral agents for hepatitis C virus‐mixed cryoglobulinaemia: dissociated virological and haematological responses
- Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018)
- Daclatasvirvstelaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
- Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
- Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
- Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience
- Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
- Chronic hepatitis D: current state of the art and emerging treatment
- Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
- [Alcoholic liver disease: current state of the problem].
- 806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION
- [Chronic HBV infection].